Results 41 to 50 of about 1,183 (178)

Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay [PDF]

ESMO Open
Peng He, Wanxiangfu Tang, Misi He
exaly   +2 more sources

Cell-Free DNA Fragmentation Patterns as Biomarkers for Human Papillomavirus-Related Cancers: A Systematic Review of Methodological Diversity and Diagnostic Performance. [PDF]

Int J Mol Sci
Novel blood biomarkers are crucial for HPV-related cancers to overcome the limitations of imaging and biopsies. This review evaluates the diagnostic performance of circulating cell-free DNA (cfDNA) fragmentomic patterns, distinguishing host-genome ...
Santos F, Silva MS, Caramelo FA, Santana MM, Nobre RJ, Tomaz JMP, Almeida LP, Figueiredo-Dias M.   +7 more
europepmc   +2 more sources

Epigenetic analysis of cell-free DNA by fragmentomic profiling

Proceedings of the National Academy of Sciences, 2022
Cell-free DNA (cfDNA) fragmentation patterns contain important molecular information linked to tissues of origin. We explored the possibility of using fragmentation patterns to predict cytosine-phosphate-guanine (CpG) methylation of cfDNA, obviating the use of bisulfite treatment and associated risks of DNA degradation.
Qing Zhou, Guannan Kang, Peiyong Jiang, Rong Qiao, W. K. Jacky Lam, Stephanie C. Y. Yu, Mary-Jane L. Ma, Lu Ji, Suk Hang Cheng, Wanxia Gai, Wenlei Peng, Huimin Shang, Rebecca W. Y. Chan, Stephen L. Chan, Grace L. H. Wong, Linda T. Hiraki, Stefano Volpi, Vincent W. S. Wong, John Wong, Rossa W. K. Chiu, K. C. Allen Chan, Y. M. Dennis Lo   +21 more
openaire   +2 more sources

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

Molecular Oncology, 2022
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit.
Daan C. L. Vessies, Milou M. F. Schuurbiers, Vincent van derNoort, Irene Schouten, Theodora C. Linders, Mirthe Lanfermeijer, Kalpana L. Ramkisoensing, Koen J. Hartemink, Kim Monkhorst, Michel M. van denHeuvel, Daan van denBroek   +10 more
doaj   +1 more source

Supplementary Figure S3 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Leave-one-out cross-validation (LOOCV) results of fragmentomics models using different ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Supplementary Figure S2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Different cross-validation results of Coxnet model using fragmentomics ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Table S1-2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Supplementary Table S1. Patient demography Supplementary Table S2. Evaluating fragmentomics model performances and ctDNA mutation-based method.
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Supplementary Figure S4 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Recursive feature elimination with cross-validation of Coxnet model using fragmentomics ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients

EMBO Molecular Medicine, 2021
Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because quantities in body fluids are low. We determined the glioma‐derived DNA fraction in cerebrospinal fluid (CSF), plasma, and urine samples from patients using ...
Florent Mouliere, Christopher G Smith, Katrin Heider, Jing Su, Ymke van der Pol, Mareike Thompson, James Morris, Jonathan C M Wan, Dineika Chandrananda, James Hadfield, Marta Grzelak, Irena Hudecova, Dominique‐Laurent Couturier, Wendy Cooper, Hui Zhao, Davina Gale, Matthew Eldridge, Colin Watts, Kevin Brindle, Nitzan Rosenfeld, Richard Mair   +20 more
doaj   +1 more source

Supplementary Figure S1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Evaluating longitudinal fragmentomics model prediction and ctDNA ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source